Skip to search formSkip to main contentSkip to account menu

sagopilone

Known as: (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-10-(prop-2-enyl)-4,17-dioxabicyclo(14.1.0)heptadecane-5,9-dione 
A fully synthetic low-molecular-weight epothilone with potential antineoplastic activity. Sagopilone binds to tubulin and induces microtubule… 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (2)

BenzothiazolesEpothilones
Microtubule ProcessNegative Regulation of Microtubule Depolymerization

Narrower (4)

ZK-219477ZK-EPOZK-Epothiloneepothilone ZK-219477

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Effect of different chronic treatment modalities on the peripheral neurotoxicity of sagopilone in rats: a multimodal analysis
Sagopilone is the first fully synthetic epothilone entered in clinical investigation for the treatment of solid tumors. Since… 
2010
2010
Gateways to clinical trials.
(-)-Epigallocatechin gallate, Abafungin, ACE-031, Adapalene/benzoyl peroxide, AE-37, Aflibercept, AGS-003, Albiglutide… 
2010
2010
Polymeric Micelles and Dendritic Amphiphiles for the Anticancer Drug Sagopilone: Solubilization, Formulation Development, and Toxicity Assessment
2009
2009
Gateways to clinical trials.
(+)-Dapoxetine hydrochloride; Abatacept, Adalimumab, Agalsidase beta, Alemtuzumab, Alglucosidase alfa, Aliskiren fumarate… 
2009
2009
DEVELOPMENT, CHARACTERIZATION AND IMAGING OF BONE METASTASIS MOUSE MODELS - THE EFFECT OF SAGOPILONE ON TUMOR GROWTH AND BONE RESORPTION -
2008
2008
Gateways to Clinical Trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2008
2008
Selected Brain Tumor Related Abstracts from ASCO 2008 (Edited by Hong Lan) Summary Table
Number Treatment NumberOfPatients PatientCatagory Outcome 13014 Accelerated RT/Temodar 28 New GBM mPFS=6m, PFS6=48%, OS1yr=48… 
2008
2008
ZK-EPO (Sagopilone) als Zweitlinientherapie bei Patienten mit Nicht-Kleinzelligem Bronchialkarzinom (NSCLC) im Stadium IIIB oder IV